<DOC>
	<DOCNO>NCT00156949</DOCNO>
	<brief_summary>Subject incidence adverse event</brief_summary>
	<brief_title>EPO Deep Tank Dialysis Subjects</brief_title>
	<detailed_description>To determine whether Epoetin alfa manufacture roller bottle technology ( Epoetin alfa RB ) Epoetin alfa manufacture deep tank process ( Epoetin alfa DT ) comparable safety profile administer patient CKD receive dialysis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>â‰¥ 18 year age Receiving hemodialysis peritoneal dialysis Baseline Hb 11.0 g/dL 13.0 g/dL Currently receive Epoetin alfa RB ie . EPOGEN PROCRIT Transferrin saturation ( Tsat ) &gt; 15.0 % Currently receive ever receive treatment erythropoietic stimulating protein EPOGEN , Procrit Aranesp . Uncontrolled hypertension ( define diastolic blood pressure &gt; 110 mmHg systolic BP &gt; 180 mmHg screening ) . Grand mal seizure within last 6 month prior screen . Acute myocardial ischemia ; hospitalization congestive heart failure myocardial infarction within 12 week enrollment . Stroke ( hemorrhagic ischemic ) transient ischemic attack within 12 week enrollment . Major surgery within 3 month prior screen ( exclude vascular access surgery ) . Clinical evidence systemic infection inflammatory disease time screen enrollment . For peritoneal dialysis subject , episode peritonitis within 30 day screen . Known positivity HIV antibody Hepatitis B surface antigen . Clinical evidence current malignancy exception basal cell squamous cell carcinoma skin . Blood transfusion within 8 week prior screen active bleeding . Androgen therapy within 8 week prior screen . Systemic hematological disease ( eg , sickle cell anemia , myelodysplastic syndrome , hematological malignancy ) ; myeloma ; hemolytic anemia . Other investigational product exclude . Subject currently enrol , yet complete , period least 30 day since end investigational device drug trial ( ) . Psychiatric , addictive , disorder compromise ability give truly informed consent participation study . Pregnant breast feeding ( woman childbearing potential must take adequate contraceptive precaution ) . Anticipating schedule livingrelated kidney transplant . Known history severe hyperparathyroidism ( PTH &gt; 1500pg/ml ) within 3 month prior top enrollment . Currently receive home hemodialysis treatment . Currently receive immunosuppressive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Epogen</keyword>
	<keyword>Procrit</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Anemia Treatment Dialysis Patients</keyword>
</DOC>